OSENI
These highlights do not include all the information needed to use OSENI safely and effectively. See full prescribing information for OSENI. OSENI (alogliptin and pioglitazone) tablets, for oral useInitial U.S. Approval: 2013
4c619ed9-fe3e-4158-9938-80c6c3493d55
HUMAN PRESCRIPTION DRUG LABEL
Dec 4, 2023
Takeda Pharmaceuticals America, Inc.
DUNS: 039997266
Products 4
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
alogliptin and pioglitazone
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (17)
alogliptin and pioglitazone
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (18)
alogliptin and pioglitazone
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (17)
alogliptin and pioglitazone
Product Details
FDA regulatory identification and product classification information